Lupus nephritis develops from a combination of genetic and environmental factors such as microbial infection. A role for microbial nucleic acids (e.g., via nucleic acid-specific Toll-like receptors [TLR]) was hypothesized, in this context, because microbial nucleic acids can trigger multiple aspects of autoimmunity in vitro and in vivo. Eight-week-old MRL lpr/lpr and MRL wild-type mice received an injection of pI:C RNA (ligand to TLR-3), imiquimod (ligand to TLR-7), or CpG-DNA (ligand to TLR-9) on alternate days for 2 wk. Only CpG-DNA triggered the onset of lupus nephritis in MRL lpr/lpr mice, as defined by diffuse proliferative glomerulonephritis associated with glomerular IgG and complement C3 deposition, proteinuria, and glomerular macrophage infiltrates. None of the compounds caused DNA autoantibody production or glomerulonephritis in MRL wild-type mice. The role of CpG-DNA to trigger lupus nephritis in MRL lpr/lpr mice was found to relate to its potent immunostimulatory effects at multiple levels: B cell IL12p40 production, B cell proliferation, double-stranded DNA autoantibody secretion, and dendritic cell IFN-␣ production. The induction of lupus nephritis by CpG-DNA is motif specific and could be prevented by co-injection of inhibitory DNA. In summary, among the ligands tested, CpG-DNA triggers lupus nephritis in genetically predisposed hosts. These data support the concept that systemic lupus erythematosus is triggered by pathogens that release CG-rich DNA.
S ystemic lupus erythematosus (SLE) usually develops from a combination of multiple susceptibility genes (1, 2) . Because most monozygotic twins are discordant for the clinical manifestations of lupus, coincident environmental factors may play a role (3) . Microbial infections are suspected to trigger the onset of lupus, similar to their postulated role in the pathogenesis of rheumatic fever or type 1 diabetes (4) . Attempts to identify a single causative pathogen have been unsuccessful, but molecular mimicry to a single pathogen epitope is unlikely to cause polyclonal lymphoproliferation in lupus. By contrast, persistent viral replication may provide a stimulus for chronic lymphoproliferation and SLE (5) . Alternatively, several pathogens could trigger autoimmunity, if susceptibility genes tune the antimicrobial immune response toward a loss of tolerance (6) . Thus, more general pathogen-associated molecular patterns (PAMP) with immunostimulatory qualities may trigger the onset of lupus in a genetically predisposed host.
The discovery of the Toll-like receptor (TLR) family has contributed significantly to our understanding of how PAMP recognition translates into innate and adaptive immune responses (7, 8) . TLR recognize PAMP that occur in all classes of microbes (e.g., diacetyl and triacetyl lipoproteins [TLR-1, -2, -6], LPS , double-stranded RNA [dsRNA; TLR-3], singlestranded RNA (TLR-7, -8), or CpG-DNA (TLR-9). In the context of SLE, the nucleic acid-related PAMP are particularly attractive in view of their potential to trigger autoimmune tissue injury. For example, exposure to PAMP that ligate TLR-3 or -7 is required to induce autoimmune diabetes in transgenic mice that harbor large numbers of pancreatic islet-reactive cytotoxic T cells (9) . In this model, the TLR-induced local production of IFN-␣ was identified to trigger the recruitment of autoreactive T cell infiltrates into the pancreatic islet. In addition, the role of TLR-3 or -9 ligation for dendritic cell maturation was also documented in a model of autoimmune myocarditis in which dendritic cells that were loaded with a heart-specific self-peptide could not induce T cell-mediated myocarditis unless being pulsed with dsRNA, LPS, or CpG-DNA (10) . After resolution of acute myocarditis, repetitive exposure to these PAMP resulted in relapse of disease. Because lymphoproliferation and autoantibody production are typical characteristics of SLE, it is noteworthy that viral single-stranded RNA and CpG-DNA can uncouple the proliferation of autoreactive B cells and autoantibody production from any control by T helper cells (11, 12) . In addition, chromatin-containing immune complexes from patients with lupus have been identified as potent inducers of IFN-␣ production, a marker of disease activity in lupus (13, 14) . Furthermore, CpG-DNA was shown to activate dendritic cells to produce IL-6, which inhibits the CD4 ϩ CD25 ϩ T cell-mediated suppression of autoreactive T cells (15) . Thus, microbial nucleic acids may represent universal PAMP that could con-tribute to the onset of lupus through multiple mechanisms, including the induction of lymphoproliferation, autoantibody production, cytokine, and type I IFN production as well as the control of autoreactive B and T cell subset (12, (15) (16) (17) . In view of these in vitro studies, we questioned whether transient exposure to dsRNA, imiquimod, and CpG-DNA would trigger lupus nephritis in vivo. In exposing young lupus-prone MRL lpr/lpr mice or nonautoimmune MRL wild-type mice to these compounds, we also addressed the role of the lpr mutation for TLR-mediated induction of autoimmune tissue injury in MRL mice. 
Materials and Methods

Animals and Experimental Protocol
Evaluation of Glomerulonephritis
Blood and urine samples were collected from each animal at the end of the study period as described (18) . Urine albumin concentration and serum dsDNA autoantibodies were determined by ELISA as described previously (19) . Urinary creatinine concentrations were determined using an automatic autoanalyzer (Integra 800; Roche Diagnostics, Mannheim, Germany). From all mice, kidneys were fixed in 10% buffered formalin, processed, and embedded in paraffin. Two-micrometer sections for periodic acid-Schiff stains were prepared following routine protocols (data not shown). The severity of the renal lesions was graded using the indices for activity and chronicity as described for human lupus nephritis (20) .
Immunostaining
Immunostaining was performed on either paraffin-embedded or frozen sections as described (18) using the following primary antibodies: Anti-mouse Mac-2 (1:50, monocytes/macrophages; BD Pharmingen, Hamburg, Germany), anti-mouse CD3 (1:100; Serotec, Oxford, UK), anti-mouse B220 (1:400, early Pro-B to mature B cells, clone RA3-6B2; BD Pharmingen), anti-mouse Ki-67 (1:100, cell proliferation; Dianova, Hamburg, Germany), anti-mouse IgG 1 (1:100, M32015; Caltag Laboratories, Burlingame, CA), and anti-mouse IgG 2a (1:100, M32215; Caltag), anti-mouse C3 (1:200, GAM/C3c/FITC; Nordic Immunological Laboratories, Tilburg, Netherlands). Negative controls included incubation with a respective isotype antibody. For quantitative analysis, glomerular cells were counted in 15 cortical glomeruli per section. Semiquantitative scoring of complement C3 deposits from 0 to 3 was performed on 15 cortical glomerular sections as described (18) .
Cell Culture Conditions and Cytokine ELISA
Bone marrow-derived dendritic cells and CD19-positive B cells were isolated from MRL and MRL lpr/lpr mice, processed, and cultured as described (21) . Cells were stimulated with 30 g/ml pI:C RNA, 3 g/ml imiquimod, 1 g/ml CpG-ODN, or medium control for 24 h, if not indicated otherwise. Cytokine levels were determined in cell supernatants using commercial ELISA kits for IL-6, IL-12p40 (OptEiA; BD Pharmingen), and IFN-␣ (PBL Biomedical Labs, Piscataway, NJ) following the protocols provided by the manufacturers.
B Cell Proliferation Assay
Proliferation of B cells was assessed using CellTiter 96 Proliferation Assay (Promega, Mannheim, Germany). In brief, 1 ϫ 10 5 B cells were incubated in 96-well plates in 100 l of RPMI medium that contained 10% FCS, 100 units/ml penicillin, and 100 g/ml streptomycin (Biochrom KG, Berlin, Germany) with TLR ligands as described previously for a period of 72 h. To each well, 20 l of CellTiter 96 Aqueous One Solution (Promega) was added and incubated at 37°C for 4 h. The optical density was measured at 492 nm using a spectrophotometric plate reader.
Statistical Analyses
Data were expressed as mean Ϯ SEM. Comparison between TLR ligand groups was performed by one-way ANOVA using the PRISM4 software (GraphPad Software, San Diego, CA). Post hoc Bonferroni correction was used for multiple comparisons. The t test was used to compare ODN 1668 ϩ 2114 versus ODN 1668. P Ͻ 0.05 indicated statistical significance.
Results
Splenomegaly and Induction of DNA Autoantibodies in Young MRL and MRL lpr/lpr Mice
At 8 wk of age, no structural abnormalities were detected in kidney and spleens of MRL wild-type mice as observed using light microscopy. Spleens of age-matched MRL lpr/lpr mice displayed lymph follicle hyperplasia with enlarged B cell zones. Renal morphology did not show any abnormalities in MRL lpr/lpr mice of this age. In MRL lpr/lpr mice, the production of autoantibodies precedes the onset of lupus nephritis (22) . Given the pathogenic role of lymphoproliferation and autoantibody production for the pathogenesis of lupus nephritis, we first tested whether exposure to nucleic acid-like PAMP induces splenomegaly and the production of DNA autoantibodies in young MRL or MRL lpr/lpr mice. In both mouse strains, spleen weight increased only with exposure to CpG-DNA ( Figure 1A ). Serum dsDNA autoantibodies were determined by ELISA in all groups of mice at 10 wk of age. In saline-treated MRL wild-type mice, serum dsDNA antibodies were absent and none of the compounds induced significant levels of dsDNA IgG autoantibodies. By contrast, 10-wk-old saline-treated MRL lpr/lpr mice had detectable levels of total IgG and IgG 1 dsDNA antibodies ( Figure 1B ). Exposure to CpG-DNA and imiquimod increased serum levels of total IgG dsDNA antibodies. In addition, CpG-DNA increased the production of IgG 2a and IgG 2b dsDNA antibodies as compared with saline-treated MRL lpr/lpr mice ( Figure 1B) . Hence, only the combination of the lpr mutation and CpG-DNA induced both splenomegaly and DNA autoantibody production in MRL mice. However, the ELISA kits for detection of IgG 2a and IgG 2b dsDNA antibodies were observed to be more sensitive compared with the total IgG ELISA kit.
B Cell Activation in MRL and MRL lpr/lpr Mice
The potential of microbial nucleic acids to induce autoantibody production in MRL lpr/lpr mice may be linked to their potential to activate B cells. The proliferation of cultured B cells that were isolated from medium-treated MRL and MRL lpr/lpr mice was comparable (Figure 2A ). CpG-DNA induced the proliferation of CD19-positive B cells that were prepared from MRL lpr/lpr but not from MRL wild-type mice. This was consistent with the marked expansion of spleen follicular B220 ϩ B cell areas in MRL lpr/lpr mice that received a injection of CpG-DNA ( Figure 2B ). Consistent with previously published data, the effect of imiquimod was less prominent in the absence of additional co-stimuli, and pI:C RNA did not affect the proliferation of B cells of either mouse strain. In fact, even 10-fold higher doses of imiquimod or pI:C RNA did not induce B cell proliferation in 8-wk-old MRL lpr/lpr mice (data not shown). CpG-DNA but not pI:C RNA increased the production of IL-12p40 in B cells that were prepared from both MRL and MRL lpr/lpr mice ( Figure 2C ). Imiquimod-induced IL-12p40 production was less potent, but in the presence of 5000 g/ml IFN-␣, imiquimod also markedly induced IL-12p40. Thus, by virtue of its effect on spleen size and autoantibody production, CpG-DNA is a potent B cell mitogen in MRL lpr/lpr mice.
Dendritic Cell Cytokine Release in MRL and MRL lpr/lpr Mice
Dendritic cells coordinate adaptive immune responses during antimicrobial immunity as well as autoimmunity. Therefore, we examined whether Ftl3 ligand-induced, CD11c-positive, ER-HR3-negative dendritic cells that were prepared from Circulating IL-12p40, IL-6, and IFN-␣ levels are markers of disease activity in lupus. Therefore, we questioned pI:C RNA-, imiquimod-, and CpG-DNA-induced changes in the respective serum levels in 10-wk-old MRL and MRL lpr/lpr mice. Serum IL12p40, IL-6, and IFN-␣ levels were determined at 3, 6, 12, and 24 h after a single agonist injection in MRL and MRL lpr/lpr mice. Baseline levels of all cytokines were low in saline-treated MRL and MRL lpr/lpr mice ( Figure 4 ). IL-12p40 was induced by imiquimod and CpG-DNA in both strains with a maximum at 6 h after injection (Figure 4) . Similarly, IL-6 was induced by pI:C RNA and CpG-DNA in both strains (Figure 4) . Serum IFN-␣ levels were low in all groups of mice and did not respond to the TLR agonists except that CpG-DNA induced the 3-h levels in MRL lpr/lpr mice ( Figure 4 ). These data suggest that IL-12p40, IL-6, and IFN-␣ serum levels are induced differently upon exposure to pI:C RNA, imiquimod, or CpG-DNA.
Lupus Nephritis in Young MRL lpr/lpr and MRL Mice
The induction of DNA autoantibody production could be associated with respective renal immune complex deposition and subsequent lupus nephritis. Therefore, we quantified glo- Figure 5 ). By contrast, injection of CpG-DNA was associated with a robust increase of capillary and mesangial staining of IgG 1 and IgG 2a ( Figure 5 , Table 1 ). Glomerular immune complexes cause glomerular damage through local complement activation. Only CpG-DNA caused marked glomerular C3 deposits in MRL lpr/lpr mice, whereas C3 staining was hardly detectable in pI:C RNA-or imiquimod-treated MR-L lpr/lpr mice and absent in MRL wild-type mice (Table 1) . Histologically, saline-treated MRL lpr/lpr mice revealed few hyaline deposits in the mesangium and focal mesangioproliferative lesions as compared with age-matched MRL wild-type mice ( Figure 5 ). Diffuse global proliferative lupus nephritis was detected only in CpG-DNA-treated MRL lpr/lpr mice ( Figure 5 ), consistent with increased numbers of Ki-67-positive proliferating glomerular cells in these mice (Table 1) . Chronic lesions such as fibrous crescents, glomerulosclerosis, interstitial fibrosis, and tubular atrophy were absent in all groups of mice. These findings also were indicated by application of the respective histologic score for disease activity of lupus nephritis (Table 1). Immunostaining for CD3 lymphocytes and Mac-2 macrophages in renal sections revealed increased numbers of glomerular macrophages in CpG-DNA-injected MRL lpr/lpr mice only ( Figure 5 , Table 1 ). CD3 lymphocytes were not found in significant numbers in kidneys of MRL and MRL lpr/lpr mice. Only CpG-DNA-treated MRL lpr/lpr mice had proteinuria indicated by an elevated urinary albumin/creatinine ratio (Table 1) . These data indicate that exposure to pI:C RNA, imiquimod, or CpG-DNA does not induce lupus nephritis in MRL wild-type mice. By contrast, CpG-DNA but not pI:C RNA or imiquimod can trigger lupus nephritis in MRL lpr/lpr mice, which is associated with enhanced cytokine production, B cell activation, dsDNA autoantibody production, glomerular immune complex deposition, and subsequent glomerular damage.
Inhibitory DNA Blocks the CpG-DNA-Induced Onset of Lupus Nephritis in MRL lpr/lpr Mice
The immunomodulatory effects of microbial DNA are thought to be motif specific, and inhibitory DNA sequences have been shown to suppress the immunostimulatory effects of CpG-DNA (23). We therefore treated additional groups of 8-wk-old female MRL lpr/lpr mice using the same injection protocol as before with saline, CpG-DNA (ODN 1668), GpC-DNA (ODN 1720), inhibitory DNA (ODN 2114), or ODN 1668 ϩ 2114. Co-injection of ODN 2114 inhibited the CpG-DNA-induced onset of lupus nephritis in young MRL lpr/lpr mice. This was documented by a significant reduction of glomerular C3 deposits, activity index for lupus nephritis, glomerular macrophages, and albuminuria and glomerular Ki-67-positive cells (Table 2 ). This was consistent with a reduction of serum IL-6 and IL-12p40 levels and a trend toward reduced spleen size and IFN-␣ levels in ODN 1668 ϩ 2114 -treated MRL lpr/lpr mice as compared with mice that were treated with ODN 1668 (Table  2) . Injections with the inhibitory ODN 2114 or the control GpC-ODN had no effect on lupus nephritis of young MRL lpr/lpr mice. These data show that the DNA-induced lupus nephritis is specific to the CpG-motif. Furthermore, inhibitory DNA elements that are delivered in synthetic ODN can prevent CpG-DNA-induced onset of lupus nephritis by suppressing CpG-DNA-induced lymphoproliferation, autoantibody production, and subsequent renal injury.
Discussion
In vitro studies suggest that microbial nucleic acids can modulate autoimmunity through multiple mechanisms, but their impact on the onset of lupus nephritis in MRL lpr/lpr mice is not known (11-13,15,17,24 -26) . We used MRL lpr/lpr and MRL wildtype mice to study the effects of an intermittent exposure to pI:C RNA, imiquimod, and CpG-DNA on lymphoproliferation and autoantibody production in genetically predisposed and nonpredisposed hosts. None of the compounds caused DNA autoantibody production or glomerulonephritis in MRL wild-type mice. By contrast, CpG-DNA but not pI:C RNA or imiquimod triggered an early onset of lupus nephritis in MRL lpr/lpr mice.
CpG-DNA Triggers Lupus Nephritis in Young MRL lpr/lpr
Mice TLR-9 is not expressed by intrinsic renal cells (18) . Hence, the potential of CpG-DNA to induce lupus nephritis in young MRL lpr/lpr mice is more likely to mediate its modulatory effects on immune cells at extrarenal sites (e.g., in lymphoid organs). In fact, the onset of lupus nephritis is thought to arise from glomerular immune complex deposition, complement activation, and subsequent glomerular inflammation (1). At 8 wk of age, MRL lpr/lpr mice are characterized by an early stage of lymphoproliferation, but serum DNA autoantibodies are still absent (22) . Thus, young MRL lpr/lpr mice represent a model of a genetically predisposed host in which overt autoimmune tissue injury (i.e., proteinuric lupus nephritis) is absent. After exposure of MRL lpr/lpr mice to dsRNA, imiquimod, and CpG-DNA, prominent glomerular deposits of IgG, the complement factor C3, diffuse proliferative glomerulonephritis, and overt proteinuria were observed exclusively in CpG-DNA-treated MRL lpr/lpr mice. Only CpG-DNA activated immunity at multiple levels (B cell cytokine production, B cell proliferation, autoantibody production, dendritic cell cytokine production, and elevation of serum IFN-␣ levels). This is consistent with previous data documenting the immunostimulatory effects of CpG-DNA in other autoimmune-prone mouse strains (27, 28) . By contrast, dsRNA and imiquimod did not induce renal disease in MRL lpr/lpr mice, despite the potential of imiquimod to trigger dsDNA autoantibody production (11) . dsRNA and imiquimod less potently triggered polyclonal B cell proliferation in young MR-L lpr/lpr mice even at a 10-fold higher dosage. TLR-7 ligands were shown previously to activate more potently preactivated B cells (29) (e.g., in the presence of IFN-␣ [30] ), an effect that we also observed in primary B cells from MRL lpr/lpr mice. However, serum IFN-␣ levels were undetectable or low in 8-wk-old MRL and MRL lpr/lpr mice, respectively. Polyclonal B cell proliferation is critical to trigger the onset of autoimmune tissue injury in MRL lpr/lpr mice and in human SLE (31, 32) . Imiquimod also failed to induce the class switch to anti-dsDNA IgG 2a , which are pathogenic in lupus nephritis and specifically induced by TLR-9 signaling (33). This may explain why dsRNA and imiquimod did not induce lupus nephritis despite their stimulatory effects on serum IL-6 and IL-12p40 levels (pI:C RNA) or anti-dsDNA total IgG production (imiquimod). We recently showed that TLR-3, -7, and -9 ligation markedly aggravates the progression of advanced lupus nephritis to a comparable extent in 16-wk-old MRL lpr/lpr mice (18, 19, 21) . This involved two additional mechanisms that apply only to MR-L lpr/lpr mice in which a renal lesion is already present at the time of exposure to TLR ligands (1) . Mesangial cell apoptosis that is induced by the same dosages of pI:C RNA can cause mesangiolysis in activated glomerular mesangial cells of nephritic MRL lpr/lpr mice (21,34). We did not observe mesangiolysis in young MRL lpr/lpr mice that were treated with pI:C RNA, indicating that the low basal expression of TLR-3 in mesangial cells of nonnephritic kidneys of MRL lpr/lpr mice does not support dsRNA-induced glomerular injury (34) . In fact, increasing the activation state of glomerular macrophages is a potent mechanism to exacerbate glomerular injury in experimental glomerulonephritis (35) (36) (37) . However, this mechanism could not operate in MRL wild-type mice or MRL lpr/lpr mice that were not treated with CpG-DNA in which glomerular macrophages were absent.
Induction of Lupus Nephritis in MRL lpr/lpr Mice by DNA is Motif Specific
In this study, none of the ODN induced lupus nephritis in MRL lpr/lpr mice except for CpG-DNA. CpG was identified to be the critical motif in bacterial DNA that mediated its immunostimulatory effects through TLR-9 (25, 38) . Inhibitory DNA sequence elements counterbalance the immunostimulatory effects of CpG-DNA, but they occur at different frequencies in microbial and vertebrate DNA (39, 40) . Inhibitory ODN can block CpG-DNA-induced effects in vitro (12, 21, 23 ). Here we show that injections with inhibitory DNA prevent CpG-DNAinduced lupus nephritis in young MRL lpr/lpr mice. This was associated with an inhibitory DNA-related suppression of CpG-DNA-induced dsDNA autoantibody production and serum IL-6, IL-12p40, and IFN-␣ levels. Thus, inhibitory DNA can antagonize the multiple motif-specific immunostimulatory effects of CpG-DNA in young lupus-prone MRL lpr/lpr mice.
CpG-DNA Does Not Induce Lupus Nephritis in MRL WildType Mice
MRL mice carry a number of susceptibility genes, of which some loci predispose to lymphoproliferation and DNA autoantibody production, whereas others predispose to either lupus nephritis or arthritis (41, 42) . Here we show that CpG-DNAinduced activation of B cells and dendritic cells does not trigger the onset of lupus nephritis in MRL mice most likely because MRL mice still are capable of controlling the number of autoreactive B cells and T cells via Fas-induced apoptotic cell death (43) . Repeated injections with CpG-DNA can cause splenomegaly and disruption of lymph follicles in nonautoimmune mice, but CpG-DNA can trigger high-affinity DNA autoantibody production in normal mice only when injected together with mammalian DNA (44, 45) .
Conclusion
Among nucleic acids and nucleic acid-like PAMP, CpG-DNA has a unique potential to trigger the onset of lupus nephritis in young autoimmune-prone MRL lpr/lpr mice. This relates to the potent immunostimulatory effects of CpG-DNA at multiple levels: B cell cytokine production, B cell proliferation, autoantibody production, dendritic cell cytokine production, and elevation of serum IFN-␣ levels. However, CpG-DNA does not trigger the onset of lupus nephritis in the presence of Fas, despite numerous other autoimmune susceptibility genes in MRL mice. These data confirm the concept of a combination of a strong genetic predisposition in the host and external factors for the pathogenesis of lupus nephritis. In addition, these data support the concept of SLE's being associated with chronic viral infections that continuously release CpG-DNA (e.g., EbsteinBarr virus) rather than those that release RNA (e.g., hepatitis C virus) (5) .
